Introduction
============

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation, which is usually progressive and typically involves clinical or pathological presentations (chronic bronchitis, emphysema and small airway disease) ([@b1-mmr-14-05-4496]). Accumulating evidence over the past decade has demonstrated that the pathology of COPD, in addition to bronchoconstriction, may be attributed to inflammation of the airways ([@b2-mmr-14-05-4496]). Inflammation occurring in airway epithelium is a defense mechanism to remove the injurious stimuli, which ensures the healing of tissues and cells. However, prolonged inflammation often causes progressive damage to the airway structure and function.

Clara cell protein (CC16), an anti-inflammatory protein secreted by epithelial Clara cells of the airways, is involved in the development of airway inflammatory diseases, including COPD and asthma ([@b3-mmr-14-05-4496]). Reduced levels of CC16 in the bronchial epithelium of COPD patients and reduction of CC16-positive epithelial cells in the small airways of asthmatics contribute to aggravation of inflammatory responses in chronic lung inflammation ([@b4-mmr-14-05-4496],[@b5-mmr-14-05-4496]). Induction of CC16 expression by gene transfection inhibits interleukin (IL)-1β-induced IL-8 expression in BEAS-2B bronchial epithelial cells by suppressing the transcriptional activity of nuclear factor (NF)-κB ([@b6-mmr-14-05-4496]). Our previous study demonstrated that recombinant rat CC16 suppressed lipopolysaccharide (LPS)-mediated inflammatory matrix metalloproteinase (MMP)-9 production through inactivation of nuclear factor κB (NF-κB) and p38 mitogen-activated protein kinase signaling pathways in rat tracheal epithelial (RTE) cells ([@b7-mmr-14-05-4496]). The anti-inflammatory properties of CC16 may render it a useful strategy for treatment of inflammatory respiratory disorders; This may be verified by the elucidation of the underlying mechanism via protein profile analysis of CC16-treated cells. Proteomics is an efficient method to identify the associated proteins that are downregulated or overexpressed in complex biological processes.

Mass spectrometry (MS)-based proteomics technologies are powerful tools used for large-scale protein identification and quantitation ([@b8-mmr-14-05-4496]). Among these techniques, label-free shotgun proteomics is highly effective for the identification of peptides and, subsequently, to obtain a global protein profile of a sample. Label-free shotgun proteomics provides a unique opportunity to measure peptides present in a sample and subsequently determine the abundance of the proteins across various samples ([@b9-mmr-14-05-4496]). Notably, label-free shotgun proteomics is suitable for applications in complex biological systems and generates faster, cleaner and simpler results ([@b10-mmr-14-05-4496]). Consequently, numerous researchers are employing label-free shotgun proteomics techniques for discovery studies ([@b11-mmr-14-05-4496],[@b12-mmr-14-05-4496]). In the present study, label-free quantitative shotgun proteomics was combined with MS to compare the protein expression profiles in RTE cells cultured in the absence or presence of LPS and recombinant CC16 (rCC16), to examine the molecular mechanisms underlying the anti-inflammatory action of rCC16.

Materials and methods
=====================

### Cell culture and drug treatment

RTE cells were purchased from the Cell Culture Center of the Chinese Academy of Medical Sciences (Beijing, China) and cultured in Minimal Essential Medium with Earle\'s Balanced Salts (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 20% fetal calf serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), 100 U/ml penicillin and 100 µg/ml streptomycin in a 5% CO2 humidified atmosphere at 37°C. rCC16 was prepared as previously described ([@b7-mmr-14-05-4496]) and stored at −70°C until use.

RTE cells were cultured in 12.5-cm diameter dishes at 1×10^8^ cells/dish, and divided into three groups. The cells were washed with phosphate-buffered saline (PBS) and cultured in serum-free media (control group), serum-free media supplemented with 0.1 µg/ml LPS (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) for 24 h (LPS treatment group) or pretreated with 2.0 µg/ml rCC16 in serum-free media for 2 h prior to 0.1 µg/ml LPS treatment for a further 24 h (rCC16 treatment group) ([@b7-mmr-14-05-4496]).

### Sample collection and protein extraction

Following drug treatment, RTE cells were trypsinized with 0.25% trypsin-EDTA (Thermo Fisher Scientific, Inc.) and cellular proteins were extracted according to standard protocols ([@b13-mmr-14-05-4496]). Briefly, all samples were resuspended in 50 µl PBS, transferred to a 1.5-ml screw-capped tube and centrifuged at 10,000 × *g* for 30 min at 4°C. Next, 100 µl lysis buffer (7 M urea and 2 M thiourea) was added into each of the samples, which were then sonicated to extract total proteins. Proteins were precipitated with trichloroacetic acid for 30 min on ice and centrifuged at 40,000 × *g* for 30 min. Protein concentrations were determined using the Qubit Protein assay kit (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol.

The protein extracts were diluted with 50 mM NH~4~HCO~3~ to a final concentration 0.5 mg/ml. Following the addition of 100 mmol/l dithiothreitol to a final concentration of 10 mmol/l, the protein fractions were mixed at 56°C for 60 min, diluted 10X with 250 mmol/l 2-iodoacetamide and incubated in the dark for 60 min. Finally, the samples were digested with trypsin (substrate to enzyme mass to mass ratio, 50:1) at 37°C for 12 h. Digested supernatant fractions were stored at −80°C prior to MS analysis.

### Liquid chromatography (LC)-tandem MS/MS analysis

The digested peptide mixtures were pressure-loaded onto a fused silica capillary column packed with 3-µm dionex C18 material \[reversed phase (RP); Phenomenex, Torrance, CA, USA\]. The RP sections of 100 Å were 15 cm long, and the column was washed with buffer A (water; 0.1% formic acid) and buffer B (can; 0.1% formic acid). Following desalting, a 5-mm, 300-µm C18 capture tip was placed in line with an Agilent 1100 quaternary HPLC (Agilent Technologies, Inc., Santa Clara, CA, USA) and analyzed using a 12-step separation.

The first step consisted of a 5-min gradient from 0 to 2% buffer B, followed by a 45-min gradient to 40% buffer B. Next, the buffer B flowed by 3-min gradient from 40 to 80% and 10-min at 80% buffer B. Following a 2-min buffer B gradient from 80 to 2%, \~20 µg tryptic peptide mixture was loaded onto the column and separated at a flow rate of 2 µl/min using a linear gradient. As peptides were eluted from the microcapillary column, they were electrosprayed directly into a micrOTOF-Q II™ mass spectrometer (Bruker Scientific Technology Co., Ltd., Beijing, China) with the application of a distal 180°C source temperature. The mass spectrometer was operated in the MS/MS (auto) mode. Survey MS scans were acquired in the time of flight (TOF)-Q II with the resolution set to a value of 20,000. Each survey scan (50\~2,500) was followed by five data-dependent tandem MS/MS scans at 2 Hz normalized scan speed.

### Bioinformatics analysis

Tandem mass spectra were searched against the mascot local host rat protein database version 2.1 (Matrix Science, Inc., Boston, MA, USA). The search results were then filtered using a cutoff of 1% as the peptide false identification rate. Peptides with a Z score \<4 or Delta-Mass \>5 ppm were rejected. The minimum number of peptides to identify a protein was set to 1. The default parameters for the quantification software, ProfileAnalysis software version 2.0, were used throughout the analysis (Bruker Scientific Technology Co., Ltd.).

Bioinformatics analysis was performed to categorize proteins based on the biological process, cellular component and molecular function using annotations in Protein Analysis Through Evolutionary Relationships (PANTHER) database version 6.1 ([www.pantherdb.org](www.pantherdb.org)) ([@b14-mmr-14-05-4496]), which is in compliance with gene ontology (GO) standards. Signaling pathway analysis was performed with the tools on the Kyoto Encyclopedia of Genes and Genome (KEGG) database ([www.genome.jp/kegg/pathway.html](www.genome.jp/kegg/pathway.html)).

The identified proteins in the various groups were analyzed for their molecular function, biological process or pathway terms in PANTHER using the binomial test ([@b15-mmr-14-05-4496]). Protein-protein interactions were obtained from the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database version 9.0 ([string-db.org/](string-db.org/)), which contains known and predicted physical and functional protein-protein interactions ([@b16-mmr-14-05-4496]). STRING in protein mode was used, and only interactions based on experimental protein-protein interactions and curated databases with confidence levels \>0.5- were retained.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

To verify the differential patterns of protein expression obtained by LC-MS/MS analysis from cells treated with rCC16 and LPS or LPS only, or untreated control cells, total RNA was extracted from each of the groups of cells using TRIzol^®^ reagent (CWBIO, Beijing, China). cDNA was synthesized using the SuperRT cDNA Synthesis Kit (cat. no. CW0741M; CWBIO, Beijing, China). Briefly, 20 µl reverse transcription mixture containing 4 µl deoxynucleotide triphosphate (dNTP) mix (2.5 mM each dNTP), 2 µl primer mix, 4 µl SuperRT buffer (5X), 1 µl SuperRT (200 U/µl), 1 µg RNA template and RNase-free water was prepared. The reaction conditions were as follows: Incubation at 42°C for 50 min followed by 85°C for 5 min using the PTC-100 Peltier Thermal Cycler (MJ Research, Inc., Waltham, MA, USA). qPCR was performed using an Applied Biosystems^®^ Real-Time PCR Instrument (Thermo Fisher Scientific, Inc.) and a SYBR^®^ Premix Ex Taq™ kit (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer\'s protocol. qPCR was conducted in a 20 µl reaction mixture containing 1 µl cDNA under the following conditions: Denaturation at 95°C for 1 min, followed by 40 cycles of denaturation at 95°C for 10 sec and annealing at 60°C for 40 sec in triplicates. The 2-ΔΔCq method ([@b17-mmr-14-05-4496]) was used to calculate the relative levels of target gene expression, and GAPDH expression was used as an internal control. The sequences of the primers used for qPCR are listed in [Table I](#tI-mmr-14-05-4496){ref-type="table"}.

### Statistical analysis

Data are presented as mean ± standard deviation for three independent experiments. Comparisons between groups were performed with the Student\'s *t*-test. Statistical analyses were performed in GraphPad Prism software version 5 (GraphPad Software, Inc., La Jolla, CA, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Proteomic analysis

Protein samples obtained from the LPS-treated, rCC16 + LPS-treated and control RTE cells were subjected to quantitative proteomic analysis using label-free shotgun proteomics involving RP fractionation and high-resolution Fourier transform MS. The resulting mass spectra were searched against the rat RefSeq protein database of 25,050 protein sequence inputs using the ProfileAnalysis search algorithm. In total, 613 non-redundant proteins were identified based on the identification of one or more unique peptides, and 122 of these proteins were revealed to be differentially expressed in the three treatment groups. Among the differentially expressed proteins, 87 were upregulated and 23 downregulated in LPS-treated RTE cells compared with control cells; and 75 were upregulated and 17 downregulated in cells treated with LPS + rCC16 compared with those treated with LPS alone.

[Fig. 1](#f1-mmr-14-05-4496){ref-type="fig"} presents a pairwise comparison of the identified proteins obtained from LPS-treated, rCC16 + LPS-treated and control RTE cells. A total of 28 proteins highly expressed in the LPS-treated group were downregulated in the rCC16 + LPS-treated group, and 21 proteins with low expression in the LPS-treated group were upregulated in the rCC16 + LPS-treated group. Of these 49 proteins, seven were downregulated in LPS-treated RTE cells, but upregulated in rCC16 + LPS-treated RTE cells, including uridine diphosphate (UDP) glycosyltransferase 1 family polypeptide A8 (UGT1A8), statin-related protein, elongation factor 1-α 1 (EF-1-α-1), adenosine triphosphatase (ATPase, H^+^-transporting, V1 subunit A, isoform 1; Atp6v1a1), DNA-dependent protein kinase catalytic subunit (DNA-PKcs), putative adenosylhomocysteinase (SAHH) 3 and caspase recruitment domain (CARD) protein 12. In addition, five proteins were observed to be upregulated in LPS-treated RTE cells and downregulated in rCC16 + LPS-treated RTE cells: Matrix metalloproteinase 9 (MMP-9), actin-related protein 3 homolog (Arp3), acidic ribosomal phosphoprotein P0, myosin heavy chain (MHC) type 10 (non-muscle) and tyrosine 3-monooxygenase ([Fig. 2](#f2-mmr-14-05-4496){ref-type="fig"}).

### Categorization of the 12 differentially expressed proteins based on GO annotation

Differentially expressed proteins were categorized as those that were downregulated in LPS-treated RTE cells, but upregulated in rCC16+LPS-treated RTE cells, or those which were upregulated in LPS-treated RTE cells but downregulated in rCC16+LPS-treated RTE cells ([Fig. 2](#f2-mmr-14-05-4496){ref-type="fig"}). To further understand these differentially expressed proteins, a GO analysis was performed with the PANTHER classification system to determine the molecular functions and associated biological processes of these 12 proteins. Based on their molecular functions, these differentially expressed proteins may be classified into five groups: Translation regulator activity (12.5%), binding (25%), enzyme regular activity (12.5%), structural molecule activity (12.5%) and catalytic activity (37.5%; [Fig. 3A](#f3-mmr-14-05-4496){ref-type="fig"}). Accordingly, these proteins were classified into eight groups of biological processes: Response to stimulus (7.7%), developmental process (7.7%), cellular process (23.1%), multicellular organismal process (7.7%), metabolic process (23.1%), biological regulation (15.4%), cellular component organization or biogenesis (7.7%) and localization (7.7%; [Fig. 3B](#f3-mmr-14-05-4496){ref-type="fig"}). These data suggest the possible molecular components and pathways involved in the transcription and energy metabolism activities of LPS and rCC16-responsive RTE cells.

### STRING protein-protein analysis of differentially expressed proteins

STRING is a database program for protein-protein interaction analysis to generate a network of interactions from a variety of sources, including various interaction databases, text mining, genetic interactions and shared pathway interactions. To further characterize the functions associated with the marked differences in the expression of the 12 proteins, these proteins were analyzed using STRING software version 9.0- Known and Predicted Protein-Protein Interactions. As presented in [Fig. 4](#f4-mmr-14-05-4496){ref-type="fig"}, the 12 differentially expressed proteins were connected with numerous proteins associated with inflammation, including tumor protein p53 (TP53) and ataxia telangiectasia-mutated kinase (ATM) ([@b18-mmr-14-05-4496]). These data indicate that an interacting network of proteins is associated with the molecular mechanisms underlying the anti-inflammatory activity of CC16.

### RT-qPCR analysis of differentially expressed proteins

To further determine the differential expression patterns of these proteins in RTE cells cultured in the absence or presence of LPS and rCC16, RT-qPCR was performed for transcriptional analyses of the differentially expressed proteins at the mRNA level, (with the exception of MMP-9, the expression of which has been previously described by our laboratory) ([@b7-mmr-14-05-4496]). As presented in [Fig. 5](#f5-mmr-14-05-4496){ref-type="fig"}, all 11 genes exhibited similar patterns of expression to their corresponding proteins, including tyrosine 3-monooxygenase, statin-related protein, UGT1A8, MHC type 10, EF-1-α-1, Arp3, CARD protein 12, acidic ribosomal phosphoprotein P0, DNA-PKcs, Atp6v1a1 and putative SAHH 3. Certain variations may exist between the levels of qPCR-determined gene expression and their proteins, including, for example, EF-1-α-1, CARD protein 12 and DNA-PKcs. These variations between protein and mRNA expression levels may be due to alterations in the regulation of protein translation and degradation ([@b19-mmr-14-05-4496]). In addition, specific processes that occur prior to translation may influence the mRNA translation efficiency. For example, the poly (A) tail length can affect transcript stability and therefore the abundance of a specific mRNA sequence ([@b20-mmr-14-05-4496]).

Discussion
==========

CC16 is an anti-inflammatory protein involved in the development of airway inflammatory diseases, including COPD. The present study has identified a differential pattern of protein expressions in RTE cells cultured in the presence or absence of LPS and rCC16 using label-free shotgun proteomics, and verified this at the mRNA level by RT-qPCR. The differentially expressed proteins of various molecular functions and associated biological processes are connected with numerous proteins involved in inflammation in a unique protein-protein interacting network. The present study provides a basis for the further understanding of the role of CC16 and its anti-inflammation activity in the development of airway diseases, including COPD.

Inflammation is one of mechanisms underlying the development of COPD. Therefore, reducing the inflammatory response is regarded as the primary interference measure for COPD patients. It is well-known that CC16 is a secretory protein with anti-inflammatory characteristics ([@b21-mmr-14-05-4496]). Reduced levels of CC16 in the bronchial epithelium or sputum supernatants of COPD patients may be a contributing factor in airway inflammations ([@b4-mmr-14-05-4496],[@b22-mmr-14-05-4496]). Consequently, administration of CC16 may be an effective treatment for COPD. Our previous study demonstrated that rCC16 inhibited the expression of COPD-contributing MMP-9 in LPS-treated RTE cells via the attenuation of NF-κB activation ([@b7-mmr-14-05-4496]). The present study has identified a network of proteins involved in the mechanisms underlying the anti-inflammatory activity of rCC16.

For example, exposure of RTE cells to LPS increased MHC type 10 expression that was abolished by further rCC16 treatment. Systemic muscle inflammation is known to be a major factor in COPD, particularly following exacerbations ([@b23-mmr-14-05-4496]). The changes of MHC perturb the function and structure of muscle ([@b24-mmr-14-05-4496]) and types IIx, IIa and I of MHC isoforms are expressed in human skeletal muscle ([@b25-mmr-14-05-4496]). The downregulation of the type I isoform, and upregulation of the type IIa isoform, has been demonstrated in patients with COPD ([@b26-mmr-14-05-4496]). In addition, reduction of MHC IIa fibers has been reported in LPS-treated fetal membranes (chorioamnionitis) ([@b27-mmr-14-05-4496]). While the reason for rCC16-reduced MHC type 10 expression remains unclear, carbonylation of MHC is well known to be degraded by the ubiquitin-proteasome pathway ([@b24-mmr-14-05-4496]). Therefore, rCC16 may be involved in the process of carbonylation of MHC type 10. In addition, the cytoskeletal protein Arp3 is important in airway smooth muscle contraction as a subunit of the Arp2/3 complex that initiates the branching of actin filaments ([@b28-mmr-14-05-4496]). A previous study revealed that the carbachol-stimulated cytoskeletal recruitment of Arp3 was upregulated at short muscle lengths and downregulated at long muscle lengths ([@b29-mmr-14-05-4496]). In the present study, Arp3 was increased in LPS-treated RTE cells, and decreased by further rCC16 treatment. Similarly, rCC16 reduced the levels of LPS-induced expression of tyrosine 3-monooxygenase, which encodes the protein, 14-3-3 η. The latter belongs to the 14-3-3 family of proteins that mediate signal transduction and are required for mitotic progression. Upregulation of 14-3-3 η has been evident in sporadic Creutzfeldt-Jakob disease, joint inflammation and head-and-neck squamous cell carcinoma ([@b30-mmr-14-05-4496]--[@b32-mmr-14-05-4496]). In accordance with this, the results of the present study demonstrated that rCC16 enhanced the expression of DNA-PKcs, which is crucial for DNA double-strand break repair and normal cell cycle progression ([@b33-mmr-14-05-4496]). High-dose CC16 has been revealed to delay the growth of immortalized bronchial epithelial cells and inhibit platelet-derived growth factor-induced airway smooth muscle cell proliferation ([@b34-mmr-14-05-4496],[@b35-mmr-14-05-4496]). CC16 knockdown *in vivo* results in augmented inflammation due to polymorphonuclear leukocyte recruitment to the air space in mice exposed to LPS ([@b36-mmr-14-05-4496]). Therefore, rCC16 may target the signaling molecules involved in cytoskeletal recruitment and mitotic progressions of bronchial epithelial cells and inflammatory cells.

In the present study, a number of proteins were identified that were downregulated by LPS and upregulated by rCC16 in RTE cells, including statin-related protein, CARD protein 12, eukaryotic translation EF-1-α-1, SAHH and acidic ribosomal phosphoprotein P0. Statin-related protein is a 57 kDa nuclear protein present in non-dividing cells ([@b37-mmr-14-05-4496]) and involved in the process of myopathy ([@b38-mmr-14-05-4496]). Although the functions of statin-related protein remain to be fully elucidated, an anti-inflammatory activity via tumor necrosis factor-α reduction has been reported for the statin-related rosuvastatin protein ([@b39-mmr-14-05-4496]). CARD proteins are scaffold proteins that function as key regulators of NF-κB signaling by providing a link between membrane receptors and NF-κB transcriptional subunits ([@b40-mmr-14-05-4496]). CARD11 and CARD14-mediated alterations in NF-κB signaling are thought to be an early event in the development of cutaneous squamous cell carcinoma and psoriasis, respectively ([@b40-mmr-14-05-4496],[@b41-mmr-14-05-4496]). CARD9 in macrophages mediates necrotic smooth muscle cell-induced inflammation by activating NF-κB ([@b42-mmr-14-05-4496]). Other CARD proteins, including CARD16, CARD17 and CARD18, negatively regulate inflammation by inhibiting the activation of caspase-1, which may induce the expression of IL-1β without altering NF-κB signaling ([@b43-mmr-14-05-4496],[@b44-mmr-14-05-4496]). EF-1-α-1 is a ubiquitously expressed GTPase that couples the hydrolysis of guanosine triphosphate (GTP) to guanosine diphosphate (GDP), with the delivery of aminoacyl transfer RNAs to the ribosome during protein translation ([@b45-mmr-14-05-4496],[@b46-mmr-14-05-4496]). In addition, it is involved in cell proliferation, cytoskeletal organization and protein degradation ([@b47-mmr-14-05-4496]--[@b49-mmr-14-05-4496]). High levels of EF-1-α-1 have been associated with survival ([@b50-mmr-14-05-4496]) and downregulation of EF-1-α-1 expression resulted in cell death ([@b51-mmr-14-05-4496]). SAHH 3 is an NAD^+^-dependent tetrameric enzyme that catalyzes the breakdown of S-adenosylhomocysteine to adenosine and homocysteine, and is therefore important in cell growth and regulation of gene expression ([@b52-mmr-14-05-4496]). Loss of SAHH function may result in global inhibition of cellular methyltransferase enzymes due to S-adenosylhomocysteine accumulation ([@b52-mmr-14-05-4496]). Acidic ribosomal phosphoprotein P0 is a structural component of the ribosome of all organisms. It interacts with trans-acting factor Mrt4 during ribosome assembly and is important for protein synthesis ([@b53-mmr-14-05-4496]). These data together suggest that rCC16 may function as an anti-inflammatory effector by altering the expression of tyrosine 3-monooxygenase, statin-related protein, CARD, eEF1A1, SAHH and acidic ribosomal phosphoprotein P0. The effect of CC16 on these proteins requires further study.

In addition, the present study demonstrated that rCC16 promoted expression of Atp6v1a1 and UGT1A8. Atp6v1a1 belongs to the respiratory electron transport chain (ETC) of oxidative phosphorylation in energy metabolism. Downregulated expression of Atp6v1a1 inhibits the efficiency of ETC and ATP synthesis ([@b54-mmr-14-05-4496]). This is consistent with the knowledge that the disorder of skeletal muscle energy metabolism is important in COPD, and that systemic inflammation alters the state of energy metabolism in peripheral muscles, causing them to dysfunction ([@b55-mmr-14-05-4496]). While UGTs are well known for their drug-metabolizing and detoxification potentials in drug toxicity ([@b56-mmr-14-05-4496]), UGT1A8 has in addition been associated with metabolism of mycophenolic acid ([@b57-mmr-14-05-4496]), raloxifene ([@b58-mmr-14-05-4496]) and piceatannol, which is a dietary polyphenol present in grapes and wine and may possess anticancer and anti-inflammatory activities ([@b59-mmr-14-05-4496]). Therefore, the anti-inflammatory action of rCC16 may be associated with the activities of skeletal muscle energy metabolism and UGT1A8.

The differentially expressed proteins of diverse functions and biological processes were linked to numerous other inflammation-associated proteins, including TP53 and ATM by protein-protein interaction analysis using STRING software. Expression of inflammatory cytokine genes may be directly induced by TP53- and ATM-dependent mechanisms upon radiation exposure in human monocytes and macrophages ([@b18-mmr-14-05-4496]). In addition, activation of pro-inflammatory pathways during COPD involves enhanced expression of TP53 and TP21 in lung fibroblasts ([@b60-mmr-14-05-4496]). However, ATM deficiency in mice delays the acute inflammatory response following myocardial infarction ([@b61-mmr-14-05-4496]). While TP53 and ATM pathways are always integrated with NF-κB signaling in inflammation ([@b62-mmr-14-05-4496]--[@b64-mmr-14-05-4496]), their role in the anti-inflammatory effect of CC16 remains to be determined.

In conclusion, the results of the present study demonstrate that label-free differential proteomics is able to reveal the protein profiles of the anti-inflammatory action of CC16 on RTE cells. The differential proteins and their interacting network of proteins identified in the present study may provide a basis for elucidating the molecular mechanisms underlying the anti-inflammatory effects of CC16. Further studies into the role of these proteins in COPD pathogenesis and its cellular and tissue models may lead to the development of novel diagnostic and therapeutic strategies for this disease.
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![Venn diagram presenting the differential expression patterns of the identified proteins. Comparisons of the differential expression patterns of the identified proteins were made as follows: (A) LPS vs. control, low expression in LPS-treated cells; (B) LPS vs. control, high expression in LPS-treated cells; (C) rCC16 + LPS vs. LPS, low expression in rCC16 + LPS-treated cells; and (D) rCC16 + LPS vs. LPS, high expression in rCC16 + LPS-treated cells. LPS, lipopolysaccharide; rCC16, recombinant Clara cell protein.](MMR-14-05-4496-g00){#f1-mmr-14-05-4496}

![Protein expression profiles of RTE cells cultured in the presence or absence of LPS and rCC16. Seven proteins were downregulated by LPS only (LPS) and upregulated by additional rCC16 treatment (LPS+rCC16), and five proteins were upregulated by LPS only (LPS) and downregulated by further rCC16 treatment (LPS+rCC16). Data are presented as fold changes (≤0.83 for downregulated proteins or ≥1.2 for upregulated proteins) averaged from three independent experiments. RTE, rat tracheal epithelial; LPS, lipopolysaccharide; rCC16, recombinant Clara cell protein. Ugt 1a8, uridine diphosphate glycosyltransferase 1 family polypeptide A8; EF-1-α-1, elongation factor 1-α 1.](MMR-14-05-4496-g01){#f2-mmr-14-05-4496}

![Gene ontology analysis of differentially expressed proteins based on (A) their molecular functions and (B) their associated biological processes, using PANTHER classification. Over-representation statistics were performed using the hypergeometric analysis and Benjamini & Hochberg False Discovery Rate correction.](MMR-14-05-4496-g02){#f3-mmr-14-05-4496}

![A network of interacting proteins associated with anti-inflammatory action of rCC16, as revealed by Search Tool for the Retrieval of Interacting Genes/Proteins analysis. rCC16, recombinant Clara cell protein.](MMR-14-05-4496-g03){#f4-mmr-14-05-4496}

![Reverse transcription-quantitative polymerase chain reaction analysis of genes coding for the differentially expressed proteins. mRNA expression levels followed a similar pattern to protein expression levels. \*P\<0.05. Ugt 1a8, uridine diphosphate glycosyltransferase 1 family polypeptide A8.](MMR-14-05-4496-g04){#f5-mmr-14-05-4496}

###### 

Quantitative profiles of the differentially expressed proteins involved in label-free quantitative proteomics analysis and primer sequences.

                                                                                          Sequences (5′-3′)        
  -------------- ---------------------------------------------------- --- ------- ------- ------------------------ -----------------------
  gi\|6756041    Tyrosine 3-monooxygenase                             8   1.961   0.854   CGAGCGATACGACGAAAT       GCTGATTATTCTCCAGGATGC
  gi\|206440     Statin-related protein                               5   0.540   1.384   GAAGAATGTGTCTGTCAAGGAC   GGGTGGTTCAGGATGATAAC
  gi\|40849846   UDP glycosyltransferase 1 family polypeptide A8      4   0.813   3.431   ATGGTCTACATTGGTGGGA      CGCTTTCTTCTCTGGAATCT
  gi\|13928704   Myosin heavy chain 10, non-muscle                    4   5.167   0.539   CAGATTCCTCTCCAACGG       GCAGCACTGAAGACACGA
  gi\|34852966   Elongation factor 1-α-1                              3   0.533   1.617   TTGTTGCTGCTGGTGTTG       TGGTGACTCAGTGAAATCCA
  gi\|34879484   Actin-related protein 3 homolog                      4   1.517   0.648   GCATCCTGGACCTCAAGA       CAGCGATTGGAATGTGTTT
  gi\|34862480   Caspase recruitment domain protein 12                4   0.826   1.782   CCACGGAGGATGAGCAGTA      GGAGGTTCTTCAGATTACCCA
  gi\|34870011   DNA-dependent protein kinase catalytic subunit       3   0.709   1.304   AGTGTTAGGTGAGGTTCATCCT   CAGTCCCTTTAGACAGCCA
  gi\|34852713   ATPase, H^+^-transporting, V1 subunit A, isoform 1   1   0.793   1.368   GAGAAGCCTCCATTTACACTG    GGTATGCTGGGTATCCACTAA
  gi\|34855075   Putative adenosylhomocysteinase 3                    2   0.613   1.417   CACTAAGGAATGGCTGGAGTT    CATCAACCTCAGAATCGCA
  gi\|57708      Acidic ribosomal phosphoprotein P0                   4   1.326   0.741   GACTACACTTTCCCACTGGC     TCCTCTGACTCTTCCTTTGC
                 GAPDH                                                                    GTGCCAGCCTCGTCTCATAG     CTTTGTCACAAGAGAAGGCAG

NCBI, National Center for Biotechnology Information; LPS, lipopolysaccharide; RTE; rat tracheal epithelial cell; CC16, Clara cell protein; UDP, uridine diphosphate; ATPase, adenosine triphosphatase.
